Nektar Meets Failure Again, This Time In Phase II Lupus Study

 
• By Alaric DeArment

Nektar, which had multiple trial failures for cancer drug bempegaldesleukin last year, and Lilly will now focus on rezpegaldesleukin in atopic dermatitis. Nektar is planning significant cost reductions.

Nektar said the Phase II study of rezpeg in SLE failed • Source: Shutterstock

Nektar Therapeutics has encountered another failure of a drug in its pipeline, this time rezpegaldesleukin moderately to severely active systemic lupus erythematosus (SLE). The trial failure means neither it nor partner Eli Lilly and Company will move forward in that indication, though the companies are discussing next steps for a Phase IIb study of it in atopic dermatitis, and Nektar executives suggested that a future path forward in lupus may still exist as well.

Nektar announced topline data on 23 February from its Phase II randomized, placebo-controlled trial of rezpegaldesleukin in adults with SLE...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.